Antiemetic prophylaxis in the context of chemotherapy
Conditions
Interventions
Group 1: In addition to their indicated chemotherapy, patients also receive dexamethasone as prophylaxis against nausea
- During a cycle of chemotherapy in the form of commercial tablets (dosage if ne
Sponsors
Universitätsklinikum Hamburg-Eppendorf
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Pediatric patients aged six and over who are treated in the Clinic for Pediatric Hematology and Oncology at the University Hospital Hamburg-Eppendorf 2. Indication for at least two cycles of dexamethasone-containing antiemetic prophylaxis in a solid oral dosage form during chemotherapy
Exclusion criteria
Exclusion criteria: 1. Lack of written consent from patients and/or legal representatives 2. Lack of ability to participate in the survey (linguistic, cognitive)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Acceptance of drug therapy with dexamethasone in different pharmaceutical forms as part of antiemetic prophylaxis in children 2. Complexity of drug therapy (subjective and objective) with dexamethasone in various dosage forms as part of antiemetic prophylaxis with children | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Assessment of parental acceptance 2. Acceptance at different ages 3. Complexity at different ages 4. Adherence to antiemetic prophylaxis with oral dexamethasone (number, timing) | — |
Countries
Germany
Contacts
Public ContactWilhelm Wößmann
Universitätsklinikum Hamburg-Eppendorf
Outcome results
None listed